Elena Orlova‐Morozova

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 140 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +7

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2019 · 92 citations

Treatment And Prevention, Antiretroviral-naive Adults, Clinical Trials +6

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax et al. · The Lancet HIV · 2017 · 35 citations · Full text

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin, Jean‐Michel Molina, Pedro Cahn et al. · The Lancet HIV · 2023 · 25 citations · Full text

First-line Therapy, Open-label Extensions, Antiviral Drug Development +7

Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection

Natalia Gankina, Viacheslav Morozov, Kathryn Kersey et al. · Clinical Drug Investigation · 2017 · 10 citations

Non-cirrhotic Patients, Hepatitis C, Viral Hepatitis +8